Notch signaling and breast cancer

Advances in Experimental Medicine and Biology

Volumn 727, Issue , 2012, Pages 241-257

  Reedijk, Michael ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA SECRETASE INHIBITOR; GEFITINIB; LETROZOLE; MK 0752; PROGESTERONE RECEPTOR; PROTEIN KINASE B; RO 4929097; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SURVIVIN; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VISMODEGIB; NOTCH RECEPTOR;

ABDOMINAL CRAMP; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL FATE; CELL LINEAGE; CELL MOTILITY; CELL PROLIFERATION; CELL RENEWAL; CELL SPECIFICITY; CELL SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; COPY NUMBER VARIATION; DIARRHEA; DRUG ERUPTION; EPITHELIAL MESENCHYMAL TRANSITION; FATIGUE; HUMAN; HYPOPHOSPHATEMIA; INTRADUCTAL CARCINOMA; MAMMARY STEM CELL; METASTASIS; MOUSE MAMMARY TUMOR ONCOVIRUS; NAUSEA; NONHUMAN; NOTCH GENE; NOTCH2 GENE; NOTCH3 GENE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; SOMATIC MUTATION; STEM CELL; TUMOR CELL; TUMOR INITIATING CELL; ANIMAL; BREAST TUMOR; FEMALE; METABOLISM; MOUSE; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

MOUSE MAMMARY TUMOR VIRUS; MUS;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MICE; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84859482094     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0899-4_18     Document Type: Article

References (119)

1. American Cancer Society Cancer facts and figures. http://www.cancer.org/ Research/CancerFactsFigures/index
2. Gallahan D, Callahan R. Mammary tumorigenesis in feral mice: Identification of a new mt locus in mouse mammary tumor virus (Czech 11)-induced mammary tumors. J Virol 1987; 61(1):66-74.
3. Gallahan D, Kozak C, Callahan R. A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J Virol 1987; 61(1):218-220.
4. Dievart A, Beaulieu N, Jolicoeur P. Involvement of Notch 1 in the development ofmouse mammary tumors. Oncogene 1999; 18(44):5973-5981.
5. Bouchard L, Lamane L, Tremblay PJ et al. Stochastic appearance of mammary tumors in transgenic mice canying the MMTV c-neu oncogene. Cell 1989; 57(6):93 1-936.
6. Jbappan C, Gallahan D, Stahle C et al. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev 1992; 6(3):345-355.
7. Smith GH. Gallahan D. Diella F et al. Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell Growth Differ 1995; 6(5):563-577.
8. Gallahan D, Jbappan C, Robinson G et al. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 1996; 56(8):1775-1785.
9. Hu C, Dievart A, Lupien M et al. Overexpression of activated murine Notch 1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol 2006; 168(3):973-990.
10. Kiaris H, Politi K, Grimm LM et al. Modulation of notch signaling elicits signature tumors and inhibits hrasl-induced oncogenesis in the mouse mammary epithelium. Am J Pathol 2004; 165(2):695-705.
11. Imatani A, Callahan R. Identification of a novel NOTCH-4 INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000; 19(2):223-23 1.
12. Stylianou S, Clarke RB, Brennan K. Abenant activation of notch signaling in human breast cancer. Cancer Res 2006; 66(3):1517-1525.
13. Weijzen S, Rizzo P, Braid M et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002; 8(9):979-986.
14. WengAP, FenandoAA, LeeW et al. Activating mutations ofNOTCH1 in human T-cell acute lymphoblastic leukemia. Science 2004; 306(5694):269-271.
15. Lee SH, Jeong EG, Yoo NJ et al. Mutational analysis of NOTCH 1, 2, 3 and 4 genes in common solid cancers and acute leukemias. Apmis 2007; 115(12):1357-1363.
16. Reedijk M, Odorcic S, Chang L et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65(18):8530-8537.
17. Dickson BC, Mulligan AM, Zhang H et al. High-level JAG! rnRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007; 20(6):685-693.
18. Pan C, Watkins O, Jiang WO. The possible conelation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004; 14(5):779-786.
19. Reedijk M, Pinnaduwage D, Dickson BC et al. JAG1 expression is associated with a basal phenotype and recunence in lymph node-negative breast cancer. Breast Cancer Res Treat 2008; 11 1(3):439-448.
20. Farnie O, Clarke RB, Spence K et al. Novel cell culture technique for primary ductal carcinoma in situ: Role ofNotch andepidermal growth factorreceptor signalingpathways. JNatlCancer Inst 2007; 99(8):616-627.
21. Andre F, Job B, DessenP et al. Molecular characterizationofbreast cancerwithhigh-resolutionoligonucleotide comparative genomic hybridization anay. Clin Cancer Res 2009; 15(2):441-451.
22. Yamaguchi N, Oyama T, Ito E et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res 2008; 68(6):1881-1888.
23. Fitzgerald K, Hanington A, Leder P. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 2000; 19(37):4191-4198.
24. Sansone P, Storci (1, Giovam]ini C et al p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stemlprogenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007; 25(3):807-815.
25. Sansone P, Storci O, Tavolari S et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 1 17(12):3988-4002.
26. Ayyanan A, Civenni O, Ciarloni L et al. Increased Wnt signaling triggers oncogenic conversion of human breastepithelialcellsbyaNotch-dependentmechanism. ProcNatlAcad SciUSA2006; 103(10):3799-3804.
27. Foltz DR, Santiago MC, Berechid BE et al. Olycogen synthase kinase-3beta modulates notch signaling and stability. Cun Biol 2002; 12(12):1006-1011.
28. Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch lCD and coordinate activation with turnover. Mol Cell 2004; 16(4):509-520.
29. Jehn BM, Dittert I, Beyer S et al. c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1. J Biol Chem 2002; 277(10):8033-8040.
30. McGill MA. McGlade CJ. Mammalian numb proteins promote Notch 1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J Biol Chem 2003; 278(25):23196-23203.
31. Mukherjee A, Veraksa A, Bauer Aet al. Regulation of Notch signalling by nonvisual beta-anestin. Nat Cell Biol 2005; 7(12):1191-1201.
32. Oberg C, Li J, Pauley Aet al. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem 2001; 276(38):35847-35853.
33. Pece S, Senesi M, Santolini E et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004; 167(2):215-221.
34. Colaluca IN, Tosoni D, Nuciforo P et al. NUMB controls p53 tumour suppressor activity. Nature 2008; 45 1(7174):76-80.
35. Rustighi A, Tiberi L, Soldano Aet al. The prolyl-isomerase Pini is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol 2009; 1 1(2):133-142.
36. Lu KP, Zhou XZ. The prolyl isomerase PIN!: Apivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007; 8(11):904-916.
37. Lange CS, Gilbert CW. Studies on the cellular basis of radiation lethality. 3. The measurement of stem-cell repopulation probability. Int J Radiat Biol Relat Stud Phys Chem Med 1968; 14(4):373-388.
38. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3(7):730-737.
39. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100(7):3983-3988.
40. Galli R, Binda E, Orfanelli U et al. Isolation and characterization oftumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64(19):70 11-7021.
41. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63(18):5821-5828.
42. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004; 432(7015):396-401.
43. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445(7123):106-110.
44. Collins AT, Beny PA, Hyde C et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65(23):10946-10951.
45. Fang D, Nguyen TK, Leishear K et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65(20):9328-9337.
46. Li C, Heidt DO, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67(3):1030-1037.
47. Prince ME, Sivanandan R, Kaczorowski Aet al. Identification of a subpopulation of cells with cancer stem cellproperties inhead andneck squamous cell carcinoma. Proc NatlAcad Sci USA 2007; 104(3):973-978.
48. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH lisa marker ofnormal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1(5):555-567.
49. Dontu G, Jackson KW, McNicholas E et al. Role of Notch signaling in cell-fate determination of human mammary stemlprogenitor cells. Breast Cancer Res 2004; 6(6):R605-615.
50. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stemlprogenitor cells. Genes Dev 2003; 17(10):1253-1270.
51. Bouras T, Pal B, Vaillant F et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 2008; 3(4):429-441.
52. Shackleton M, Vaillant F, Simpson KJ et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439(7072):84-88.
53. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stemlprogenitor cell properties. Cancer Res 2005; 6503):5506-5511.
54. Korkaya H, Wicha MS. HER-2, notch and breast cancer stem cells: Targeting an axis of evil. Clin Cancer Res 2009; 15(6):1845-1847.
55. Wilson A, Radtke F. Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Left 2006; 580(12):2860-2868.
56. van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005; 11(11):496-502.
57. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1):4429-4434.
58. Lee CW, Simm K, Liu Q et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008; 10(6):R97.
59. Lee CW, Raskett CM, Prudovsky I et al. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 2008; 6803):5273-5281.
60. Bane AL, Pinnaduwage D, Colby S et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 2008.
61. Cohen B, Shimizu M, Izrailit J et al. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res Treat 2010; 123(1):113-124.
62. Rizzo P, Miao H, D'Souza G et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008; 6803):5226-5235.
63. Osipo C, Patel P, Rizzo P et al. ErbB-2 inhibition activates Notch-l and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 2008; 27(37):50 19-5032.
64. Radtke F, Wilson A, Stark G et al. Deficient T-cell fate specification in mice with an induced inactivation ofNotch1. Immunity 1999; 10(5):547-558.
65. Buono KD, Robinson GW, Martin C et al. The canonical NotchIRBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol 2006; 293(2):565-580.
66. Raouf A, Zhao Y, To K et al. Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 2008; 30): 109-118.
67. Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15(8):907-913.
68. KlinakisA, SzabolcsM, Politi Ket al. Mycis aNotch1 transcriptionaltargetandarequisiteforNotch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci USA 2006; 103(24):9262-9267.
69. Arnold A, Papanikolaou A. Cyclin D1 inbreast cancer pathogenesis. J Clin Oncol 2005; 230 8):421 5-4224.
70. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of Gl-phase progression. Genes Dev 1999; 1302):1501-1512.
71. Ronchini C, CapobiancoAJ. InductionofcyclinD1 transcriptionandCDK2 activitybyNotch(ic): Implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001; 2107):5925-5934.
72. Stahl M, Ge C, Shi Set al. Notch1-induced transformation of RKE-l cells requires up-regulation of cyclin Dl. Cancer Res 2006; 6605):7562-7570.
73. Rowan S, Conley KW, Le TT et al. Notch signaling regulates growth and differentiation in the mammalian lens. Dev Biol 2008; 321(1):111-122.
74. Campa VM, Gutierrez-Lanza R, Cerignoli F et al. Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. J Cell Biol 2008; 1830):129-141.
75. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411(6841):1017-1021.
76. Meurette O, Stylianou S, Rock R et al. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 2009; 6902):5015-5022.
77. Altieri DC. Survivin, cancernetworksandpathway-directeddrugdiscovery. NatRevCancer2008; 8(1):61-70.
78. Timmerman LA, Grego-Bessa J, Raya A et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 2004; 18(1):99-l15.
79. Vincent-SalomonA, Thiery JP. Host micro environment in breast cancer development: Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res 2003; 5(2):101-106.
80. Leong KG, Niessen K, Kulic Jet al. Jaggedi-mediatedNotch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007; 204(12):2935-2948.
81. Martin TA, Goyal A, Watkins G et al. Expression of the transcription factors snail, slug and twist and their clinical significance in human breast cancer. Ann Surg Oncol 2005; 12(6):488-496.
82. Noguera-Troise I, Daly C, Papadopoulos NJ et al. Blockade of Dll4 inhibits tumour growth by promoting nonproductive angiogenesis. Nature 2006; 444(7122):1032-1037.
83. Mailhos C, Modlich U, Lewis J et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001; 69(2-3): 135-144.
84. Zeng Q, Li S, Chepeha DB et al. Crosstalk betweentumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005; 8(1):13-23.
85. Soares R, Balogh G, Guo S et al. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol 2004; 18(9):2333-2343.
86. Callahan R, Egan SE. Notch signaling in mammary development and oncogenesis. J Mammary Gland Biol Neoplasia 2004; 9(2):145-163.
87. Hao L, Rizzo P, Osipo C et al. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene 29(2):201-213.
88. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008; 8(4):324-333.
89. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed afler chemotherapy for metastatic disease. J Clin Oncol 1999; 17(9):2639-2648.
90. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3):719-726.
91. Chen Y. Fischer WH. Gill GN. Regulation of the ERBB-2 promoter by RBPlkappa and NOTCH. J Biol Chem 1997; 272(22):14110-14114.
92. Shih Ic M, Wang TL. Notch signaling, gamma-secretase inhibitors and cancer therapy. Cancer Res 2007; 67(5):1879-1882.
93. Kopan R, Goate A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev 2000; 14(22):2799-2806.
94. Konishi J, Kawaguchi KS, Vo H et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007; 67(17):805 1-8057.
95. Qin JZ, Stennett L, Bacon P et al p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004; 3(8):895-902.
96. Rao SS, O'Neil J, Liberator CD et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 2009; 69(7):3060-3068.
97. O'Neill CF, Urs S, Cinelli C et al. Notch2 signaling induces apoptosis and inhibits human MDA-MB-23 1 xenografl growth. Am J Pathol 2007; 171(3):1023-1036.
98. Mittal S, Subramanyam D, Dey D et al. Cooperation of Notch and Ras MAPK signaling pathways inhuman breast carcinogenesis. Mol Cancer 2009; 8:128.
99. Watters JW, Cheng C, Majumder PK et al. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 2009; 69(23):8949-8957.
100. Radtke F, Clevers H, Riccio O. From gut homeostasis to cancer. Cun Mol Med 2006; 6(3):275-289.
101. Barten DM, Meredith JE Jr, Zaczek Ret al. Gamma-secretase inhibitors for Alzheimer' s disease: Balancing efficacy and toxicity. Drugs RD 2006; 7(2):87-97.
102. Lammich S, Okochi M, Takeda Met al. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 2002; 277(47):44754-44759.
103. Marambaud P, Shioi J, Serban Get al. A presenilin-1 gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002; 21(8): 1948-1956.
104. Ni CY, Murphy MP, Golde TE et al. gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294(5549):2 179-2181.
105. NickoloffBJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: A new approach to the development of cell fate modifying agents. Oncogene 2003; 22(42):6598-6608.
106. Krop IE, Kosh M, Fearen I et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol 2006; 24(18S): 10574.
107. Albain K. A pilot study of MK-0752 in combination with tamoxifen or letrozole in patients with early stage breast cancer prior to surgery. http://clinicaltrials.gov/ct2/show/NCT00756717.
108. ToicherAW, Mikulski SM, WAM et al. Aphase I study ofR04929097, anovel gamma secretase inhibitior, in patients with advanced soli tumors. J Clin Oncol 2010; 28(155): 2502
109. LoRusso PM. Aphase I dose-excalation study ofthe Hedgehog Smoothened antagonist GDC-0449 (NSC# 747691) pius pan-Notch Inhibitor R04929097(NSC# 749225) administered in patients with advanced breast cancer http://clinicaltrials.gov/ct2/show/NCT01071564.
110. LawsonND, VogelAM, WeinsteinBM. sonic hedgehog andvascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Developmental cell 2002; 3(1): 127-136.
111. Nickoloff BJ, Qin JZ, Chaturvedi V et al. Jagged-1 mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ 2002; 9(8):842-855.
112. Moss ML, Stoeck A, Yan W et al. ADAM 10 as a target for anti-cancer therapy. Cun Pharm Biotechnol 2008; 9(1):2-8.
113. Hokaiwado N, Takeshita F, Banas Aet al. RNAi-based drug discovery and its application to therapeutics. IDrugs 2008; 1 1(4):274-278.
114. Ma J, Meng Y, Kwiatkowski DJ et al. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3 p63 Jagged/Notch cascade. J Clin Invest 120(1):103-1 14.
115. Ridgway J, Zhang O, Wu Y et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444(7122): 1083-1087.
116. Hoey T, Yen WC, Axeirod F et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009; 5(2):168-177.
117. Yan M, Callahan CA, Beyer JC et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 463(7282):E6-7.
118. Antonio J, Chiorean EG, LoRusso P. A Phase 1, multiple-dose study of the safety and tolerability of single-agent REQJN42 1 administered every 2 or 3 weeks in patients with advanced solid malignancies. http://clinicaltrials.gov/ ct2/show/NCTOO871559.
119. Eisenberg P. Talpaz. M. A phase 1 dose escalation study of OMP-2 1M18 in subjects with solid tumors. http://clinicaltrials.gov/ct2/show/NCT00744562.